ANTIBODIES TO TGFBETA

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF.beta.), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF.beta.1, TGF.beta.2, and TGF.beta.3, so...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LEDBETTER, STEVEN R, HART, CELIA P, HOLGATE, ROBERT G, BUCHANAN, CATRIONA L, JERMUTUS, LUTZ U, FINCH, DONNA K, DUNCAN, ALEXANDER R
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF.beta.), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF.beta.1, TGF.beta.2, and TGF.beta.3, so-called "pan-specific" antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). La présente invention concerne des molécules d'anticorps, en particulier des molécules d'anticorps qui fixent le facteur de croissance transformant bêta (TGF.beta.), et leurs applications. L'invention concerne plus particulièrement des molécules d'anticorps qui fixent et, de préférence, neutralisent, TGF.beta.1, TGF.beta.2 et TGF.beta.3, des molécules d'anticorps dites =, et leurs applications. Les modes de réalisation préférés de la présente invention concernent des molécules d'anticorps, à savoir des anticorps totaux (des IgG, tels que IgG1 ou IgG4, par exemple) ou des fragments d'anticorps (scFv, Fab, dAb, par exemple).